![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will support the preclinical development of the Company’s senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
Lead Product(s): Senotherapy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Emerging Longevity Ventures
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Financing March 18, 2024
Details:
The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.
Lead Product(s): Oligonucleotide-based Thearpy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undislcosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding April 20, 2023